Who is sponsoring NCT03878914?

NCT03878914 is sponsored by Wayne State University.

What drugs are being tested in NCT03878914?

Interventions in NCT03878914: Corticosteroids.

What condition does NCT03878914 study?

NCT03878914 studies Nephrotic Syndrome in Children.

Is NCT03878914 still recruiting?

NCT03878914 is currently terminated. Last updated 2 May 2022.

Last reviewed 2022-05-02 · How we verify

NCT03878914

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Steroid Sensitive Nephrotic Syndrome in Children

Terminated Phase 4 Last updated 2 May 2022

What this trial tests

Phase 4 trial testing Corticosteroids in Nephrotic Syndrome in Children in 34 participants. Terminated before completion.

Timeline

6 August 2019

Primary endpoint
31 October 2021

31 October 2021

Quick facts

Lead sponsor	Wayne State University
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	34
Start date	6 August 2019
Primary completion	31 October 2021
Estimated completion	31 October 2021
Sites	2 locations across China, United States

Drugs / interventions tested

Corticosteroids (corticosteroids) — full drug profile →

Conditions studied

Nephrotic Syndrome in Children — all drugs for Nephrotic Syndrome in Children →

Sponsor

Wayne State University

Who can join

Adults 1 to 18, any sex, with Nephrotic Syndrome in Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Idiopathic nephrotic syndrome (INS) is one of the most common glomerular pathologies in children and corticosteroid therapy is its most effective treatment. The total duration of treatment ranges anywhere from two to six months, generally about 3 months. The main objective of our study is to test the feasibility of a shorter total duration (two months) of corticosteroid therapy in patients who show a quicker treatment response to the initial treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome.
Liu J, Deng F, Wang X, Liu C, et al · · 2024 · cited 9× · PMID 38707815 · DOI 10.1016/j.ekir.2024.02.1395
Duration of initial prednisolone therapy for first episode of childhood nephrotic syndrome based on time to response.
Tang X, Shen Q, Rao J, Chen J, et al · · 2022 · cited 1× · PMID 36405821 · DOI 10.3389/fped.2022.1043285

Verify or expand the search:

Other trials of Corticosteroids

Trials testing the same drug.

NCT07297914 — Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL · Phase 2, PHASE3 · not yet recruiting
NCT07340723 — Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease ) · Phase 2 · recruiting
NCT07565844 — Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia · NA · recruiting
NCT06585774 — A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease · Phase 3 · recruiting
NCT06388564 — A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Dia · Phase 2 · recruiting

Other recruiting trials for Nephrotic Syndrome in Children

Currently open trials in the same condition.

NCT07091175 — Dupilumab Therapy in Nephrotic Syndrome in Children · Phase 2 · recruiting
NCT07087314 — A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequen · Phase 2 · recruiting
NCT06635720 — REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE) · Phase 3 · recruiting
NCT06125405 — Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome · Phase 3 · recruiting
NCT06079788 — Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospe · Phase 3 · recruiting

Other Wayne State University trials

Trials by the same sponsor.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07123467 — Cannabidiol-Assisted Learning for Managing Generalized Anxiety Disorder · Phase 3 · recruiting
NCT07222306 — Cannabis, Neuroinflammation, and Suicidal Ideation: A Supplemental Brain Imaging Study · enrolling by invitation
NCT05684978 — Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus · Phase 4 · terminated
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03878914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wayne State University
Last refreshed: 2 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03878914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing